Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fengyinhe Holdings | Hong Kong | Financials | Investment Banking & Investment Services | 77.8% | HK$261.20M | 0.9x | -0.16 | HK$0.77 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Investment and Finance | Hong Kong | Financials | Investment Banking & Investment Services | 45.5% | HK$330.08M | -19.5x | -0.25 | HK$0.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dynamic | Hong Kong | Real Estate | Real Estate Operations | 35.5% | HK$2.47B | 0.5x | 0 | HK$10.38 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Everest Med | Hong Kong | Healthcare | Pharmaceuticals | 31.4% | HK$2.44B | -6.2x | HK$38.40 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
OSL | Hong Kong | Technology | Financial Technology (Fintech) & Infrastructure | 24.8% | HK$4.96B | -21.9x | -0.55 | HK$7.89 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.4% Downside | Upgrade to Pro+ | |
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | 20.9% | HK$2.99B | -180x | -1.75 | HK$4.68 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CL | Hong Kong | Financials | Investment Banking & Investment Services | 17.9% | HK$114.40M | 4.7x | 0.03 | HK$0.05 | 8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zhaoke Ophthalmology | Hong Kong | Healthcare | Pharmaceuticals | 7.8% | HK$759.13M | -3.1x | -0.06 | HK$1.40 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MGM China Holdings | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | 7% | HK$39.67B | 8.8x | 0.03 | HK$10.48 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Sunwah Kingsway Capital | Hong Kong | Financials | Investment Banking & Investment Services | 5.2% | HK$171.98M | -3x | -0.11 | HK$0.23 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Emperor Capital | Hong Kong | Financials | Investment Banking & Investment Services | 2% | HK$343.78M | 5.1x | 0.04 | HK$0.05 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sands China | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | 1.2% | HK$144.87B | 17.5x | 0.07 | HK$17.90 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.3% Upside | Upgrade to Pro+ | |
Orient Securities Int | Hong Kong | Financials | Banking Services | 0% | HK$19.49M | 6.9x | 0.02 | HK$0.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pinestone Capital | Hong Kong | Financials | Investment Banking & Investment Services | -0.9% | HK$57.12M | -4.8x | -0.07 | HK$0.21 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | -3.2% | HK$13.92B | -0.3x | -1.68 | HK$131 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.1% Upside | Upgrade to Pro+ | |
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | -4.2% | HK$253.50M | -0.4x | -0.14 | HK$2.92 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galaxy Entertainment Group | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -6.2% | HK$137.28B | 16.5x | 0.01 | HK$31.40 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.1% Upside | Upgrade to Pro+ | |
Yinsheng Digifavor | Hong Kong | Technology | Telecommunications Services | -10.3% | HK$1.10B | 27.8x | 0.15 | HK$2.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Merchants China Direct | Hong Kong | Financials | Investment Banking & Investment Services | -10.7% | HK$2.07B | 174.6x | 1.6 | HK$13.60 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tong Tong AI Social | Hong Kong | Financials | Banking Services | -10.8% | HK$1.59B | 11.9x | 0.03 | HK$0.30 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Melco Int Development | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -12.6% | HK$5.15B | -4.9x | -0.07 | HK$4.09 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.7% Upside | Upgrade to Pro+ | |
Holly Futures Co | Hong Kong | Financials | Investment Banking & Investment Services | -13% | HK$2.74B | 110.5x | 1.4 | HK$2.73 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | -14.4% | HK$13.49B | -5.5x | 0.46 | HK$13.44 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | -15.8% | HK$13.64B | -30.5x | -0.5 | HK$42.95 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
Capital Estate | Hong Kong | Financials | Investment Banking & Investment Services | -17.5% | HK$64.13M | 11.3x | 0.1 | HK$0.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
E Station Green Tech | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -18.4% | HK$15.68M | 0.3x | 0 | HK$0.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ARTA TechFin | Hong Kong | Financials | Investment Banking & Investment Services | -24.5% | HK$800.01M | -18.5x | -0.32 | HK$0.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT Capital | Hong Kong | Financials | Investment Holding Companies | -26.8% | HK$166.85M | -17.7x | -0.27 | HK$0.06 | 17.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | -29.2% | HK$1.05B | -5.9x | 0.71 | HK$0.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Graphene | Hong Kong | Real Estate | Real Estate Operations | -36.7% | HK$400.22M | 21x | 0.38 | HK$0.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |